Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

This publication has 21 references indexed in Scilit:

• Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
  Journal of Clinical Oncology, 1998
• Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration
  Leukemia & Lymphoma, 1997
• Filgrastim (r-metHuG-CSF): the first 10 years
  Blood, 1996
• Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
  Journal of Clinical Oncology, 1995
• Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
  Journal of Clinical Oncology, 1995
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
  European Journal Of Cancer, 1993
• Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
  Blood, 1992
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
  New England Journal of Medicine, 1991
• Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.
  Journal of Clinical Oncology, 1989
• Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
  New England Journal of Medicine, 1988